BIOMARIN PHARMACEUTICAL INC (BMRN)       82.87  -1.97 (-2.32%)

Oversold Conditions For BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical and Economic Review (ICER) released a Draft...

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks showing resilience.

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization...

June 2024 Options Now Available For BioMarin Pharmaceutical (BMRN)

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

SAN RAFAEL, Calif., July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman...

BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...

BioMarin’s Gene Therapy Nears European Market After US Setback

BioMarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker’s hopes it can succeed where rival Bluebird Bio Inc. faltered.

BioMarin Pharmaceutical Larger Than S&P 500 Component Quest Diagnostics

First Week of BMRN September 16th Options Trading

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

Four pharmaceutical stocks, including three biotech movers, are making big moves.

BMRN June 2023 Options Begin Trading

BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Incl...

Commitment to Advancing Care for People with Hemophilia A Demonstrated with Largest and Longest, Ongoing Clinical Development Program for any Gene...